X

Trial Profile

Adalimumab in COVID-19 to present respiratory failure in community care (AVID-CC): A randomised controlled trial

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 28 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Adalimumab (Primary)
Indications COVID-19 respiratory infection
Focus Therapeutic Use
Acronyms AVID-CC

Most Recent Events

20 Oct 2021 Status changed from active, no longer recruiting to discontinued due to participant recruitment issue. The trial will not go ahead due to the success of the vaccine roll-out in care homes, there were very few people in the target population who remained eligible for the study.
04 Oct 2020 Status changed from not yet recruiting to recruiting.
24 Aug 2020 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com